|
US6410516B1
(en)
|
1986-01-09 |
2002-06-25 |
President & Fellows Of Harvard College |
Nuclear factors associated with transcriptional regulation
|
|
US5206152A
(en)
|
1988-04-08 |
1993-04-27 |
Arch Development Corporation |
Cloning and expression of early growth regulatory protein genes
|
|
DE3815221C2
(de)
|
1988-05-04 |
1995-06-29 |
Gradinger F Hermes Pharma |
Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
|
|
KR100225087B1
(ko)
|
1990-03-23 |
1999-10-15 |
한스 발터라벤 |
피타아제의 식물내 발현
|
|
US5272056A
(en)
|
1991-01-03 |
1993-12-21 |
The Research Foundation Of State University Of New York |
Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
|
|
CA2106386A1
(en)
|
1991-04-18 |
1992-10-19 |
Barbara C. F. Chu |
Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
|
|
FR2675803B1
(fr)
|
1991-04-25 |
1996-09-06 |
Genset Sa |
Oligonucleotides fermes, antisens et sens et leurs applications.
|
|
AU659482B2
(en)
|
1991-06-28 |
1995-05-18 |
Massachusetts Institute Of Technology |
Localized oligonucleotide therapy
|
|
EP0771320A4
(en)
|
1993-07-29 |
1998-11-25 |
Univ California |
POLYNUCLEOTIDE LURES INHIBITING THE EXPRESSION OF MAJOR II HISTOCOMPATIBILITY COMPLEX, AND APPLICATIONS
|
|
PT732929E
(pt)
|
1993-10-29 |
2008-08-26 |
Brigham & Womens Hospital |
Utilização terapêutica de ''engodos'' de elementos cis in vivo
|
|
AU3881095A
(en)
|
1994-11-17 |
1996-06-17 |
Taiho Pharmaceutical Co., Ltd. |
Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
|
|
WO1996029433A1
(en)
|
1995-03-23 |
1996-09-26 |
Research Foundation Of State University Of New York |
Rest protein and dna
|
|
ATE271128T1
(de)
|
1995-05-11 |
2004-07-15 |
Applied Research Systems |
Inhibitoren der il-6 aktivitaet
|
|
ES2285712T3
(es)
|
1995-05-12 |
2007-11-16 |
Anges Mg, Inc. |
Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b.
|
|
GB9515356D0
(en)
|
1995-07-26 |
1995-09-20 |
Medical Res Council |
Improvements in or relating to delivery of nucleic acid
|
|
US6265389B1
(en)
|
1995-08-31 |
2001-07-24 |
Alkermes Controlled Therapeutics, Inc. |
Microencapsulation and sustained release of oligonucleotides
|
|
US6245747B1
(en)
|
1996-03-12 |
2001-06-12 |
The Board Of Regents Of The University Of Nebraska |
Targeted site specific antisense oligodeoxynucleotide delivery method
|
|
EP1011729B1
(en)
|
1996-05-20 |
2008-01-09 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Oligonucleotides which specifically bind retroviral nucleocapsid proteins
|
|
US6022863A
(en)
|
1996-05-21 |
2000-02-08 |
Yale University |
Regulation of gene expression
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
US6890909B1
(en)
|
1997-07-04 |
2005-05-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Brain-protective agent
|
|
JP3667047B2
(ja)
|
1997-09-12 |
2005-07-06 |
キヤノン株式会社 |
人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
|
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
|
US6376471B1
(en)
|
1997-10-10 |
2002-04-23 |
Johns Hopkins University |
Gene delivery compositions and methods
|
|
US6060310A
(en)
|
1997-11-24 |
2000-05-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Transcription factor decoy and tumor growth inhibitor
|
|
AU1656299A
(en)
|
1997-12-16 |
1999-07-05 |
University Of Saskatchewan |
Conductive metal-containing nucleic acids
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
IL139936A0
(en)
|
1998-06-02 |
2002-02-10 |
Glaxo Group Ltd |
Gene therapy method
|
|
US6818626B1
(en)
|
1998-07-17 |
2004-11-16 |
Mirus Corporation |
Chelating systems for use in the delivery of compounds to cells
|
|
US6423493B1
(en)
|
1998-10-26 |
2002-07-23 |
Board Of Regents The University Of Texas System |
Combinatorial selection of oligonucleotide aptamers
|
|
US6008048A
(en)
|
1998-12-04 |
1999-12-28 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of EGR-1 expression
|
|
US7115396B2
(en)
|
1998-12-10 |
2006-10-03 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US7160869B2
(en)
|
1998-12-16 |
2007-01-09 |
University Of Saskatchewan |
Biologically active metal-containing nucleic acids
|
|
IL143734A0
(en)
|
1998-12-23 |
2002-04-21 |
Genentech Inc |
Transfectacons comprising calcium phosphate and a nucleic acid
|
|
US6395029B1
(en)
|
1999-01-19 |
2002-05-28 |
The Children's Hospital Of Philadelphia |
Sustained delivery of polyionic bioactive agents
|
|
US6333408B1
(en)
|
1999-03-08 |
2001-12-25 |
Kureha Chemical Industry Co., Ltd. |
Oligonucleotides inhibitors of PAI-1 MRNA
|
|
FR2790955B1
(fr)
|
1999-03-19 |
2003-01-17 |
Assist Publ Hopitaux De Paris |
Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
|
|
US6387620B1
(en)
|
1999-07-28 |
2002-05-14 |
Gilead Sciences, Inc. |
Transcription-free selex
|
|
CA2300328A1
(en)
|
1999-09-14 |
2001-03-14 |
Cardiogene Gentherap. Systeme Ag |
Modulating transcription of genes in vascular cells
|
|
US6927027B2
(en)
|
1999-12-21 |
2005-08-09 |
Ingeneus Corporation |
Nucleic acid multiplex formation
|
|
US6969704B1
(en)
|
2000-08-25 |
2005-11-29 |
The Trustees Of Columbia University In The City Of New York |
Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
|
|
EP1332209B1
(en)
|
2000-09-08 |
2009-11-11 |
Universität Zürich |
Collections of repeat proteins comprising repeat modules
|
|
US6376190B1
(en)
|
2000-09-22 |
2002-04-23 |
Somalogic, Inc. |
Modified SELEX processes without purified protein
|
|
DE10049549A1
(de)
*
|
2000-10-06 |
2002-05-02 |
Markus Hecker |
Modulation der Transkription pro-inflammatorischer Genprodukte
|
|
US20040192598A1
(en)
|
2000-10-11 |
2004-09-30 |
Laura Kragie |
Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
EP1344536A4
(en)
|
2000-11-24 |
2005-01-19 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR REGULATING THE EFFECT OF THE EXPRESSION PRODUCT OF A GENE TRANSFERRED IN A LIVING BODY
|
|
US20020137715A1
(en)
|
2001-01-03 |
2002-09-26 |
Alain Mauviel |
Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis
|
|
US7060690B2
(en)
|
2001-01-22 |
2006-06-13 |
Genta Incorporated |
Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
|
|
EP1362600B1
(en)
|
2001-02-20 |
2008-04-02 |
AnGes MG, Inc. |
TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
|
|
US20070122401A1
(en)
|
2001-03-06 |
2007-05-31 |
Andrews William H |
Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
|
|
US20030166555A1
(en)
|
2001-04-02 |
2003-09-04 |
Alberini Cristina M. |
Methods and compositions for regulating memory consolidation
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20030082630A1
(en)
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
|
US20040175756A1
(en)
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
|
EP1298141A1
(en)
|
2001-09-27 |
2003-04-02 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2
|
|
DE10148828B4
(de)
|
2001-10-04 |
2005-05-19 |
Avontec Gmbh |
Modulation der Expression STAT-1-abhängiger Gene
|
|
US6663880B1
(en)
|
2001-11-30 |
2003-12-16 |
Advanced Cardiovascular Systems, Inc. |
Permeabilizing reagents to increase drug delivery and a method of local delivery
|
|
CN1697647A
(zh)
|
2002-02-01 |
2005-11-16 |
奥默罗斯公司 |
用于抑制疼痛,炎症和软骨退化的溶液及方法
|
|
US7244592B2
(en)
|
2002-03-07 |
2007-07-17 |
Dyax Corp. |
Ligand screening and discovery
|
|
CN1240439C
(zh)
|
2002-03-28 |
2006-02-08 |
南京凯基生物科技发展有限公司 |
肿瘤基因开关药物
|
|
US20070014840A1
(en)
|
2002-04-26 |
2007-01-18 |
In-Kyu Lee |
Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
|
|
DE10242319A1
(de)
|
2002-09-12 |
2004-03-25 |
Avontec Gmbh |
Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
|
|
KR20120068035A
(ko)
|
2002-12-09 |
2012-06-26 |
아브락시스 바이오사이언스, 엘엘씨 |
약리학적 물질의 조성물 및 그 전달방법
|
|
DE10257421A1
(de)
|
2002-12-09 |
2004-07-08 |
Grünenthal GmbH |
Regulatorische Elemente im 5'-Bereich des VR1-Gens
|
|
EP1644532A4
(en)
|
2003-06-30 |
2007-11-28 |
Massachusetts Inst Technology |
EGR GENES AS OBJECTIVES FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA
|
|
WO2005027830A2
(en)
|
2003-09-12 |
2005-03-31 |
Virginia Commonwealth University |
Chimeric transcription factor decoy oligonucleotides
|
|
US8372966B2
(en)
|
2003-12-19 |
2013-02-12 |
University Of Cincinnati |
Oligonucleotide decoys and methods of use
|
|
JP2005336081A
(ja)
|
2004-05-26 |
2005-12-08 |
Anges Mg Inc |
Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
|
|
US7482158B2
(en)
|
2004-07-01 |
2009-01-27 |
Mathison Brian H |
Composite polynucleic acid therapeutics
|
|
WO2006012625A2
(en)
|
2004-07-22 |
2006-02-02 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Stat3 decoy oligonucleotides and uses therefor
|
|
AU2005286640A1
(en)
|
2004-09-21 |
2006-03-30 |
Anesiva, Inc. |
Delivery of polynucleotides
|
|
AU2005288522B2
(en)
|
2004-09-28 |
2012-06-28 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
|
|
US8067384B2
(en)
|
2004-10-22 |
2011-11-29 |
Anges Mg, Inc. |
Chimera (double) decoy
|
|
US7585848B2
(en)
|
2005-01-11 |
2009-09-08 |
Rush University Medical Center |
Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
|
|
WO2006096498A2
(en)
|
2005-03-04 |
2006-09-14 |
Dana-Farber Cancer Institute, Inc. |
Regulation of runx1 for treatment of pain
|
|
EP1877556B1
(en)
|
2005-03-25 |
2011-09-14 |
Medtronic, Inc. |
Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain
|
|
EP2086573B1
(en)
|
2006-10-09 |
2020-11-25 |
Neurofluidics, Inc. |
Cerebrospinal fluid purification system
|
|
CN101686939B
(zh)
|
2007-04-17 |
2013-03-27 |
巴克斯特国际公司 |
用于肺部投送的核酸微粒
|
|
AU2014201462B2
(en)
*
|
2007-05-11 |
2016-09-29 |
Adynxx, Inc. |
Gene expression and pain
|
|
US7943591B2
(en)
*
|
2007-05-11 |
2011-05-17 |
Adynxx, Inc. |
Gene expression and pain
|
|
GB0906130D0
(en)
*
|
2008-10-03 |
2009-05-20 |
Procrata Biosystems Ltd |
Transcription factor decoys
|
|
US8609617B2
(en)
*
|
2009-09-04 |
2013-12-17 |
University Of Miami |
KLF family members regulate intrinsic axon regeneration ability
|
|
BR112013003875B1
(pt)
|
2010-08-20 |
2021-10-05 |
Replicor Inc |
Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
|
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
EP2734212B1
(en)
|
2011-07-20 |
2017-09-06 |
Hospira, Inc. |
Compositions comprising diclofenac for the treatment of post-operative pain
|
|
PT2846839T
(pt)
|
2012-05-10 |
2019-05-29 |
Adynxx Inc |
Formulações para a administração de ingredientes ativos
|
|
SMT202100319T1
(it)
|
2012-05-18 |
2021-09-14 |
Replicor Inc |
Composizioni e metodi del complesso oligonucleotide chelato polipeptidico
|
|
RU2017108238A
(ru)
|
2014-08-15 |
2018-09-17 |
Эйдинкс, Инк. |
Олигонуклеотиды-приманки для лечения боли
|
|
WO2017151644A1
(en)
|
2016-02-29 |
2017-09-08 |
Adynxx, Inc. |
Compositions and methods for pain amelioration via modification of gene expression
|
|
EP3755345A1
(en)
|
2018-02-23 |
2020-12-30 |
Adynxx Sub, Inc |
Compositions and methods for pain amelioration in patient population that scores high on the pain catastrophizing scale
|